In a recent study posted to the medRxiv* preprint server, a team of researchers performed a meta-analysis of the results of four previous studies estimating fold-drop in neutralization titer against Omicron to present a combined estimate of the same. In addition, they estimated the protection conferred by the previous infection with ancestral severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2) strain vis-a-vis symptomatic and severe Omicron infection.
Study: Analysis: A meta-analysis of Early Results to predict Vaccine efficacy against Omicron. Image Credit: Viacheslav Lopatin/Shutterstock
This news article was a review of a preliminary scientific report that had not undergone peer-review at the time of publication. Since its initial publication, the scientific report has now been peer reviewed and accepted for publication in a Scientific Journal. Links to the preliminary and peer-reviewed reports are available in the Sources section at the bottom of this article. View Sources
Omicron (B.1.1.529), declared a variant of concern (VOC) by the World Health Organization in November 2021, is known for escaping the host’s natural immune responses and most of the available vaccines due to the mutations in its spike (S) protein. Since December 2021, four laboratories have reported the estimates of a drop in neutralization titer against Omicron in the range of 2- to over 20-fold.
Several previous large meta-analyses of the neutralization of other SARS-CoV-2 VOCs have shown that the drop in neutralization against a variant varies dramatically between laboratories and assays. The results also depend on the limit of detection of the assay and the potency of the serum. The authors of this study aggregated a range of estimates from multiple laboratory reports rather than relying on a single laboratory result.
About the study
In this study, the researchers collated data from four previous studies. They presented a combined estimate of the fold-drop in neutralization titer against Omicron after accounting for the laboratory and censoring effects of neutralization titers below the detection limit. Vaccine efficacy against that VOC could also be determined once the loss of neutralization titer against a novel VOC is known. Therefore, the researchers used a previously developed method for estimating vaccine efficacy based on neutralization titers. They predicted vaccine efficacy against Omicron shortly after vaccination, six months later, and the impact of a booster dose of mRNA vaccine.
Results
The study results showed a combined estimate of the drop in neutralization titer against Omicron of 9.7-fold. In addition, the results showed that prior infection from an ancestral SARS-CoV-2 strain conferred 34.3% protection against symptomatic Omicron infection and 76.6% protection in severe cases.
Consistent with the results of previous research studies, the researchers observed that following primary vaccination, the protection conferred by the ChAdOx1 nCoV-19 vaccine was similar to the protection given by prior infection, but the mRNA vaccines conferred higher protection. However, six months after primary immunization with an mRNA vaccine, vaccine efficacy against Omicron waned to around 40% for symptomatic and 80% for severe disease cases, which increased to 86.2% after a booster dose.
Conclusions
Overall, the study results suggest that the Omicron variant can escape natural and vaccine-induced immunity. However, it is still possible to achieve high levels of protection to symptomatic and severe infection from Omicron by boosting doses with existing vaccine dosage that target SARS-CoV-2 S protein. The vaccine efficacy estimates of this study were compared with the data from test-negative case-control study published by UK Health Security Agency as both were in good agreement. This further validated the findings of this study in the context of vaccine efficacy.
This news article was a review of a preliminary scientific report that had not undergone peer-review at the time of publication. Since its initial publication, the scientific report has now been peer reviewed and accepted for publication in a Scientific Journal. Links to the preliminary and peer-reviewed reports are available in the Sources section at the bottom of this article. View Sources
Article Revisions
- May 9 2023 - The preprint preliminary research paper that this article was based upon was accepted for publication in a peer-reviewed Scientific Journal. This article was edited accordingly to include a link to the final peer-reviewed paper, now shown in the sources section.
Thrombotic thrombocytopenic purpura cases after CoronaVac raise concerns over vaccine safety